Engflag

Omesel

Quick links to important sections

Omesel

Omesel_EN

Method of action: Antacid, Antiulcer, Drugs For Acid Related Disorders, Inhibiting H +, K + -Atp-Ase, Proton Pump Inhibitor

Treatment option: Duodenal Ulcer, Heartburn, Reflux, Esophageal Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Helicobacter Pylori, Esophagitis, Stomach Ulcer, Peptic Ulcer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omesel

Quick Facts

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule or tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid
Origin Synthetic, substituted benzimidazole

Defining Omesel: An Antisecretory Agent and Proton Pump Inhibitor

Omesel is a synthetic pharmaceutical preparation used to effectively control the production of acid in the stomach. The medicine's foundation lies in its active ingredient, Omeprazole, which is classified as a potent Proton Pump Inhibitor (PPI). Omeprazole is widely recognized as one of the earliest and most frequently prescribed molecules in its class, with its efficacy supported by decades of pharmacological studies. This chemical designation places it within the most effective category of compounds available for sustained suppression of gastric acid. Omesel's fundamental purpose is to aid in the management of conditions arising from the presence of excessive or inappropriate amounts of stomach acid, such as frequent, persistent heartburn.

Composition, Origin, and Specialized Formulation

The active ingredient, Omeprazole, is a synthetic compound derived from the substituted benzimidazole class. It is frequently formulated as a salt, such as Omeprazole magnesium, to improve stability and bioavailability. Because the Omeprazole compound is highly susceptible to rapid degradation by the acid in the stomach, the drug is designed as a specialized delayed-release or gastro-resistant dosage form, such as a capsule or tablet. This essential protective coating ensures that the medication remains intact as it passes through the stomach and is subsequently absorbed in the small intestine, thereby maximizing the intended therapeutic effect. The necessity of this specialized coating for Omeprazole's absorption and efficacy is a key factor differentiating its delivery system.

General Therapeutic Purpose and Action Principle

Omesel's general purpose is to provide powerful, sustained reduction of the acid secreted into the stomach cavity. This action is achieved because Omeprazole targets the acid-producing cells in the stomach lining, effectively shutting down the final, critical mechanism of acid production. Clinically recognized for its ability to suppress gastric basal and stimulated acid secretion, Omeprazole is a standard benchmark in its class. Unlike some later PPIs, Omeprazole is available globally in both prescription and lower-dose, non-prescription over-the-counter (OTC) forms. This potent antisecretory effect helps in promoting a significantly less acidic internal environment, providing a necessary physiological setting to reduce irritation caused by acidic contact.

Regulatory References

  1. National Institutes of Health (NIH) MedlinePlus

What side effects are possible with Omesel?

Possible side effects and safety information

The safety profile of Omesel (Omeprazole) is based on classifications established by government regulatory agencies, which categorize adverse reactions by frequency and affected body system. The most Common adverse reactions documented in regulatory sources include headache, abdominal pain, diarrhea, nausea, vomiting, and flatulence. These effects primarily involve the Nervous System and Gastrointestinal disorders System-Organ Classes.

Serious and Duration-Related Safety Patterns

Official labeling describes certain serious adverse reactions, which, while Rare, are clinically significant. These include Acute Tubulointerstitial Nephritis (a kidney condition) and Severe Cutaneous Adverse Reactions (such as Stevens-Johnson Syndrome). Hypersensitivity reactions, including anaphylactic shock, are also documented as rare events.

Safety notes specify patterns related to the duration of use. Long-term therapy (typically one year or longer) is associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, and Hypomagnesemia (low blood magnesium). Additionally, prolonged use may lead to Cyanocobalamin (Vitamin B-12) deficiency and the development of Benign Fundic Gland Polyps.

Safety Constraints and Special Populations

The regulatory safety information emphasizes that a symptomatic response to Omesel does not preclude the presence of gastric malignancy. Furthermore, PPI therapy may be associated with an increased risk of Clostridium difficile-Associated Diarrhea.

For specific populations, individuals with hepatic impairment may require particular consideration due to the drug's metabolism. In pediatric patients and the elderly, the general safety profile is similar to adults, although the fracture risk is heightened with long-term, high-dose exposure, as stated in official documents.

Overdose and Emergency Response

Overdose and when to seek help

The following information is strictly based on the official overdose sections found in government regulatory documents.

Overdose Scope

Category Official Regulatory Statements
Documented overdose presentations Clinical manifestations may include headache, nausea, vomiting, abdominal pain, diarrhea, and drowsiness. Other effects documented are confusion, blurred vision, tachycardia (rapid heartbeat), dry mouth, and flushing.
Physiological systems affected Central Nervous System (CNS) and potential, though rare, Cardiovascular system effects.
Dose-related or exposure-related factors Documented reports of acute, high-level ingestion (up to 2,400 mg daily) have not consistently resulted in severe, life-threatening clinical outcomes.
Population-specific overdose notes The overall safety profile and clinical manifestations of overdose are generally considered similar in pediatric patients compared to adults.

Overdose Classifications (High-Level)

Category Official Regulatory Statements
Severity classification Symptoms are typically classified as mild and transient based on documented reporting.
Overdose-context constraints No specific antidote is known to counteract the effects of an overdose.

Resulting Overdose Structure

Official overdose statements:

  • Immediate Action Mandate: Regulatory guidance requires seeking immediate medical attention or contacting a Poison Control Center regardless of whether symptoms are currently present.
  • Management Procedure: Treatment is strictly defined as symptomatic and supportive, which may involve hospital monitoring of vital signs and continuous clinical status observation.

Connection to the overall overdose profile (2–4 sentences): The official regulatory profile for Omesel overdose establishes that while the clinical manifestations are generally mild and transient, the absence of a specific reversal agent necessitates mandatory, immediate professional medical intervention. This approach ensures that patients receive required symptomatic and supportive care and monitoring as defined by health authorities.

Therapeutic Uses of Omesel

Quick Facts: Uses of Omesel

  • Gastroesophageal Reflux Disease (GERD): May help address symptoms like heartburn.
  • Erosive Esophagitis: May support the healing and maintenance of the esophagus lining.
  • Ulcer Management: Can be used for the short-term treatment of active duodenal or gastric ulcers.
  • H. pylori: Used in combination with other agents to address Helicobacter pylori infection, which may help reduce the risk of ulcer recurrence.
  • Hypersecretory Conditions: May be used for the long-term management of conditions that involve the oversecretion of gastric acid, such as Zollinger-Ellison syndrome.

Omesel is prescribed for the management of conditions associated with gastric acid production. Its primary therapeutic domain is in addressing acid-related disorders in adults and pediatric patients. For symptomatic Gastroesophageal Reflux Disease (GERD), Omesel may help resolve heartburn and related symptoms. The medication is also indicated for the short-term treatment of active benign gastric ulcer and active duodenal ulcer. Clinical data supports its use in these areas.

Furthermore, Omesel may be used to support the healing of erosive esophagitis and maintain that healing. In cases involving the bacteria H. pylori, the drug is used as part of a combination regimen to reduce the risk of duodenal ulcer recurrence. Finally, it is an option for the long-term management of specific, severe conditions characterized by the pathological oversecretion of acid.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for Omesel is strictly defined by regulatory authorities based on age, concurrent medication use, and specific health conditions.

Classification Official Regulatory Wording
Absolute Contraindication Patients with a known hypersensitivity to omeprazole or any component of the formulation. Also, co-administration with rilpivirine-containing products is prohibited.
Age-Related Rules Approved for adults across all licensed uses. Use is approved for children as young as 1 month of age for specific conditions (e.g., erosive esophagitis), but safety is not established in infants younger than 1 month of age for all indications.
Conditional Use (Organ Function) Hepatic impairment (liver dysfunction) requires special consideration; regulatory documents suggest a dose reduction may be necessary due to altered drug clearance. No dose adjustment is generally specified for renal impairment.
Reproductive Status Use during pregnancy is generally considered acceptable, as epidemiological data suggests major malformative risks are unlikely. The drug is excreted in breast milk at low levels and is not expected to cause adverse effects in breastfed infants.

Eligibility is also restricted by a clinical precaution: symptomatic improvement in adults does not preclude the presence of gastric malignancy, and diagnostic follow-up is necessary before continued use.

What should I know about interactions with other medicines?

Omesel Interactions with other medicines and products

Official regulatory information structures Omesel’s interaction profile around two primary pharmacokinetic mechanisms: gastric pH modification and CYP2C19 enzyme inhibition.

Documented Interaction Restrictions

Interaction Type Interacting Agent Regulatory Constraint
Gastric pH (Decreased Absorption) Atazanavir, Nelfinavir Co-administration is not recommended due to significant reduction in antiretroviral plasma levels.
CYP2C19 (Pro-drug Inhibition) Clopidogrel Co-administration should be avoided due to diminished anti-platelet activity.
Reduced Omesel Exposure Rifampin, St. John's Wort Use should be avoided due to potential reduction in Omesel plasma concentrations.

Exposure Modification and Monitoring

Omesel’s inhibition of the CYP2C19 enzyme system prolongs the elimination and increases the exposure of several co-administered medicines, including Phenytoin, Diazepam, Warfarin, and Cilostazol. Conversely, increased gastric pH requires monitoring of agents such as Digoxin (increased absorption) and decreases the bioavailability of drugs like Ketoconazole and Erlotinib.

Timing-Based and Procedural Constraints

The interaction profile includes required timing constraints. Temporary withdrawal of Omesel must be considered during high-dose Methotrexate administration due to the risk of elevated serum concentrations. Furthermore, Omesel must be stopped at least 14 days before assessing Chromogranin A (CgA) levels to prevent interference with diagnostic results.

Mechanism of Action

Targeting the Final Acid Pump

Omesel acts as an irreversible inhibitor of the H^+, K^+-ATPase enzyme (the proton pump), which is situated in the parietal cells of the stomach lining and constitutes the final step in gastric acid secretion. The drug is administered in an inactive form (a prodrug) and requires the highly acidic environment within the parietal cell canaliculi to be chemically converted into its active sulfonamide form. This process ensures the mechanism is localized at the site of acid production. The active form then forms a covalent and lasting bond with the proton pump, permanently disabling its function. This inactivation stops the transport of hydrogen ions ( H^+) into the stomach lumen. The mechanistic result is a sustained and predictable reduction of hydrogen ion concentration and the prolonged elevation of the gastric pH, which persists until the body manufactures new enzyme pumps.

Dosage and Administration Information

How Omesel is Used: Official Administration Guidelines

Omesel (Omeprazole) is primarily administered via the oral route using delayed-release capsules or tablets, but an intravenous (IV) formulation is also available for use in clinical settings when the oral route is not feasible. The administration pattern is structured to ensure the medicine's integrity and proper absorption, which is why the oral delayed-release dosage form must be taken before eating, ideally in the morning.

For nearly all standard regimens, Omesel is taken once daily. However, for specific conditions that require high doses, such as severe pathological hypersecretory states (Zollinger-Ellison syndrome), the total daily dosage may be divided and taken multiple times per day.

Dosing and Duration Principles

Indication Context Standard Adult Dose / Schedule Typical Duration
Symptomatic GERD / Healing Erosive Esophagitis 20 mg once daily 4 to 8 weeks
Active Gastric Ulcer 40 mg once daily 4 to 8 weeks
Hypersecretory Conditions (Initial) 60 mg once daily (often divided) Long-term

All patients receiving the delayed-release form are instructed to swallow the tablet or capsule whole and must not chew, crush, or split the dosage unit, as this would compromise the protective enteric coating. In cases where a dose is missed, it should be taken promptly unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. A potential dose reduction may be necessary for patients with severe hepatic impairment, with 20 mg once daily often cited as a maximal dose in these cases.

Recent Clinical Evidence

Research evidence / Overview of studies for Omesel

Evidence for Symptom Management in GERD and Heartburn

Research examining the study of Omeprazole in individuals with Gastroesophageal Reflux Disease (GERD) and frequent heartburn relies primarily on short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing the observed patterns with those seen in patients receiving an inactive treatment (placebo) or other acid-reducing compounds. Researchers monitored patient-reported outcomes describing perceived discomfort, specifically focusing on the frequency and intensity of heartburn, as well as outcomes reflecting daily functioning or activity level during the study period.

Findings describe patterns observed in these short-term studies, and research highlights reported changes measured in symptoms of physical discomfort after several weeks of study. Data show patterns related to measured differences in patient-reported outcomes when Omeprazole was administered compared to placebo. However, the existing controlled evidence is largely focused on these short-term treatment protocols—typically lasting around two months. This means there is limited information for long-term outcomes regarding symptomatic control or changes in daily-life functioning beyond this initial period.

Research on Resolution and Maintenance of Erosive Esophagitis

Omeprazole was studied for in research contexts involving erosive esophagitis (damage to the esophageal lining caused by acid). The key research design for this condition involved short-term clinical trials that tracked a primary physical outcome: endoscopic resolution of mucosal breaks. Subsequent intermediate-term RCTs, often lasting up to a year, were observed in patients who had already achieved initial resolution. The primary focus of these follow-up studies was to monitor the prevention of symptomatic relapse and the recurrence of mucosal breaks over the defined observation periods.

Follow-up durations were limited in these controlled maintenance studies, rarely extending beyond 12 months. Therefore, long-term effects are not fully established regarding sustained resolution over many years. Furthermore, Omeprazole was evaluated in studies including specific age groups where evidence may otherwise be limited, such as in pediatric patients (infants and children), although data for certain groups remain insufficient when compared to the large volume of data available for adults.

What Research Gaps and Uncertainties Remain

The research landscape for Omeprazole contributes significantly to the broader evidence landscape, yet several gaps and uncertainties exist. The majority of high-quality controlled evidence is short-term, and there is limited information for long-term outcomes. For the study in H. pylori infection, findings were mixed due to the constant variability of antibiotic resistance patterns, and research is ongoing to find the most effective combination regimens. Research findings describe group patterns, not personal outcomes, which is a common limitation of all clinical trials.

Key Studies & References

  1. Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs
  2. Use of omeprazole in patients with Zollinger-Ellison syndrome (Long-term follow-up review)

Frequently Asked Questions (FAQ)

Common questions about Omesel (FAQ)

Q: Does it make you sleepy?

A: Official safety documents indicate that drowsiness or somnolence (sleepiness) has been reported as a common side effect during clinical trials. Because this effect may vary among individuals, it is listed in the product information.

Q: Is it safe to take this drug with alcohol?

A: The official product information includes a specific warning about alcohol use. Regulatory warnings indicate that co-administration with alcohol may increase the risk of certain central nervous system side effects, such as dizziness or increased drowsiness.

Q: Can children 2 years old use it?

A: The approved labeling for Omesel specifies limitations regarding use in children. According to regulatory documents, the safety and effectiveness of this medicine have not been established in patients under the age of 12 years.

Q: What is the correct way to store the tablets?

A: Official product information provides specific guidance on storage. Omesel tablets should be kept at controlled room temperature, which is typically between 20 C to 25 C (68 F to 77 F). Regulatory information also advises protection of the tablets from moisture.

Q: Is it safe to take it for more than 6 months?

A: The long-term safety of Omesel is based on controlled clinical trials. These studies primarily evaluated use for periods up to 12 weeks. The official label does not include a specific statement or safety data regarding continuous use beyond this time frame.

How should Omesel be stored and disposed of?

Omesel (omeprazole) must be stored and handled according to specific regulatory requirements to maintain stability and ensure safety.

Official Storage Conditions

The solid dosage form (capsules/tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine requires protection from light and moisture and must be kept in its original container with the bottle kept tightly closed.

Special Handling and Child Safety

Do not freeze the capsules or tablets. The medicine must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Omesel must be disposed of in accordance with local requirements. The medicine should not be thrown away via wastewater or household waste; patients are advised to consult a pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagVietnam

Equivalent of Omesel found in:

A-Z Index: